Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer
Authors:
Open Access
- 27 June 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (6) , e67195
Abstract
Methylated DNA in fluids may be a suitable biomarker for cancer patients. XAF1 has been shown to be frequently down-regulated in human gastric cancer (GC). Here, we investigated if XAF1 methylation in GC could be a useful biomarker. Real-time RT-PCR was used to detect XAF1 mRNA expression; immunohistochemistry and western blot were used to examine XAF1 protein expression in GC tissues (n = 202) and their corresponding para-cancerous histological normal tissues (PCHNTs). Real-time methylation specific-PCR was used to investigate XAF1 promoter methylation in the same panel of GC tissues, their PCHNTs and sera. We confirmed frequent XAF1 down-regulation in both mRNA and protein levels in GC tissues as compared to normal controls and PCHNTs. XAF1 hypermethylation was evidenced in 83.2% (168/202) of GC tissues and 27.2% (55/202) of PCHNTs, while no methylation was detected in the 88 normal controls. The methylation level in GC tissues was significantly higher than that in PCHNTs (p<0.05). The hypermethylation of XAF1 significantly correlated with the down-regulation of XAF1 in GC tissues in both mRNA and protein levels (pXAF1 methylation (69.8%, 141 out of 202) in the sera DNAs from the same patients, while the sera DNAs from 88 non-tumor controls were negative for XAF1 methylation. The XAF1 methylation in both GC tissues and in the sera could be a good biomarker for diagnosis of GC (AUC = 0.85 for tissue and AUC = 0.91 for sera) and significantly correlated with poorer prognosis (pXAF1 methylation in sera strongly associated with tumor recurrence. 1) Dysfunction of XAF1 is frequent and is regulated through XAF1 promoter hypermethylation; 2) Detection of circulating methylated XAF1 DNAs in the serum may be a useful biomarker in diagnosis, evaluating patient’s outcome (prognosis and recurrence) for GC patients.Keywords
This publication has 34 references indexed in Scilit:
- MSH2 promoter hypermethylation in circulating tumor DNA is a valuable predictor of disease-free survival for patients with esophageal squamous cell carcinomaEuropean Journal of Surgical Oncology, 2012
- Aberrant Methylation of Different DNA Repair Genes Demonstrates Distinct Prognostic Value for Esophageal CancerDigestive Diseases and Sciences, 2011
- Hypermethylation-modulated down-regulation of CDH1 expression contributes to the progression of esophageal cancerInternational Journal of Molecular Medicine, 2011
- Hypermethylation-modulated Downregulation of RASSF1A Expression Is Associated with the Progression of Esophageal CancerArchives of Medical Research, 2011
- IgH gene rearrangements as plasma biomarkers in Non-Hodgkin's Lymphoma patientsOncotarget, 2011
- IAPs: from caspase inhibitors to modulators of NF-κB, inflammation and cancerNature Reviews Cancer, 2010
- DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinomaGut, 2008
- Correlation Between the Single-Site CpG Methylation and Expression Silencing of the XAF1 Gene in Human Gastric and Colon CancersGastroenterology, 2006
- Histological Grading in Gastric Cancer by Ming Classification: Correlation with Histopathological Subtypes, Metastasis, and PrognosisWorld Journal of Surgery, 2005
- Hypermethylation of XIAP-associated factor 1, a putative tumor suppressor gene from the 17p13.2 locus, in human gastric adenocarcinomas.2003